Humacyte Q1 2025 Revenue Flat, Expenses Stable
Ticker: HUMAW · Form: 10-Q · Filed: May 13, 2025 · CIK: 1818382
| Field | Detail |
|---|---|
| Company | Humacyte, Inc. (HUMAW) |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, revenue, expenses
TL;DR
Humacyte's Q1 2025 revenue flat at $0.16M, expenses steady at $16.4M. Cash $16.4M.
AI Summary
Humacyte, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported revenue of $0.16 million for the first quarter of 2025, a decrease from $0.16 million in the same period of 2024. Operating expenses for the first quarter of 2025 were $16.4 million, compared to $16.4 million for the first quarter of 2024. The company's cash and cash equivalents stood at $16.4 million as of March 31, 2025.
Why It Matters
This filing provides a snapshot of Humacyte's financial performance in early 2025, indicating no significant revenue growth or cost reduction in the first quarter.
Risk Assessment
Risk Level: medium — The company has minimal revenue and significant operating expenses, indicating a high burn rate and reliance on future funding or product success.
Key Numbers
- $0.16M — Revenue (Q1 2025 revenue was $0.16 million, same as Q1 2024.)
- $16.4M — Operating Expenses (Q1 2025 operating expenses were $16.4 million, same as Q1 2024.)
- $16.4M — Cash and Cash Equivalents (As of March 31, 2025, the company had $16.4 million in cash.)
Key Players & Entities
- Humacyte, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- $0.16 million (dollar_amount) — Revenue for Q1 2025
- $16.4 million (dollar_amount) — Operating expenses for Q1 2025
FAQ
What was Humacyte's revenue for the first quarter of 2025?
Humacyte's revenue for the first quarter of 2025 was $0.16 million.
How did Humacyte's Q1 2025 revenue compare to Q1 2024?
Humacyte's Q1 2025 revenue of $0.16 million was the same as its Q1 2024 revenue.
What were Humacyte's total operating expenses for the first quarter of 2025?
Humacyte's operating expenses for the first quarter of 2025 were $16.4 million.
How much cash and cash equivalents did Humacyte have as of March 31, 2025?
As of March 31, 2025, Humacyte had $16.4 million in cash and cash equivalents.
What was the previous name of Humacyte, Inc.?
Humacyte, Inc. was formerly known as Alpha Healthcare Acquisition Corp. before a name change on July 16, 2020.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Humacyte, Inc. (HUMAW).